Prawo i regulacje · 24/05/2021

FDA Maintains Lasmiditan in Schedule V of Controlled Substances Act

The Drug Enforcement Administration has finalized a rule placing lasmiditan, a medication used to treat migraine, in Schedule V of the Controlled Substances Act, maintaining its current classification without change, except for a minor amendment to its placement ordering.